Pasithea Therapeutics Corp. has announced significant progress in its clinical development of PAS-004, a treatment aimed at neurofibromatosis type 1 (NF1). The company reported positive initial data from its ongoing Phase 1/1b study, showcasing substantial reductions in tumor size for patients. This advancement is particularly noteworthy as it signifies a potential breakthrough in a condition lacking FDA-approved systemic treatments.
On November 13, 2026, Pasithea presented these findings at the European Neurofibromatosis Conference in Vienna. The data revealed that all 15 evaluable participants in the study experienced reductions in cutaneous neurofibromas (cNF), with a median best reduction of 41% across all doses. The FDA has also cleared the company's Investigational New Drug application for a Phase 2 trial of PAS-004 in adults with NF1-associated cNF.
This development is crucial for Pasithea as it positions the company to advance its clinical programs and potentially address a significant unmet medical need in the pharmaceutical preparations sector.
Background
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on developing innovative treatments for neurofibromatosis and other conditions. The company operates under the Standard Industrial Classification (SIC) of 2834, which pertains to Pharmaceutical Preparations. Pasithea trades on the Nasdaq under the ticker symbol KTTA. Recent filings include an 8-K on November 16, 2026, and a Schedule 13G/A on the same day, indicating ongoing corporate activities.
What the Filing Says
The filing details the positive initial results from the Phase 1/1b study of PAS-004. According to the report, "All participants showed cutaneous neurofibroma (cNF) reductions: All 15 evaluable participants had reductions in target cNF surface area, with a median best reduction of 41% across all doses and 46% at doses planned for Phase 2." Additionally, the FDA's clearance for a Phase 2 trial marks a significant milestone for the company.
Impact
This announcement may significantly impact patients suffering from neurofibromatosis, as PAS-004 presents a new treatment option in a field where current therapies are limited. The positive data could also influence investors and stakeholders interested in the pharmaceutical preparations sector. Competitors in this space may need to reassess their strategies in light of Pasithea's promising results.
What's Next
Following this filing, Pasithea is expected to proceed with the Phase 2 trial, although specific details regarding the timeline or additional filings were not disclosed in the current report.
Read Next
Alpha Tau Medical Reports Positive Interim Results from REGAIN Trial
TOYO Co., Ltd Reports Q3 2026 Results in Latest Filing
NN Inc. to Present at Craig-Hallum Alpha Select Conference
Fresco Gutierrez Diego sells shares of StoneCo Ltd.
Ciena Corp appoints new Chief Product Officer amid changes
Shell plc's Dick Boer Nominated for Philips Supervisory Board









